Purpose: To retrospectively determine whether relative cerebral blood volume (CBV)
measurements can be used to predict clinical outcome in patients with high-grade gliomas (HGGs) …

Background. Primary central nervous system non‐Hodgkin's lymphoma (NHL‐CNS) is an
enigmatic disease of uncertain origin. At the Massachusetts General Hospital, 104 patients …

✓ The treatment of primary central nervous system lymphoma with chemotherapy prior to
whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously …

Object Antiangiogenic agents have recently shown impressive radiological responses in
high-grade glioma. However, it is not clear if the responses are related to vascular changes or …

Object The presence of angiogenesis is a hallmark of glioblastoma (GBM). Vascular
endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target for …

✓ Malignant oligodendrogliomas have been shown to be responsive to chemotherapy. The
authors administered systemic chemotherapy to seven patients with oligodendroglioma or …

The prognosis for patients with recurrent malignant glioma is poor. Both temozolomide and
irinotecan have been shown to be active in this disease. A study was performed combining …

BACKGROUND AND PURPOSE: Dynamic, contrast-enhanced MR imaging has allowed
quantitative assessment of cerebral blood volume (CBV) in brain tumors. The purpose of our …

We evaluate the effects of adjuvant treatment with the angiogenesis inhibitor Avastin (bevacizumab)
on pathological tissue specimens of high-grade glioma. Tissue from five patients …

INTRODUCTION: Bevacizumab, a monoclonal antibody against vascular endothelial
growth factor (VEGF), has shown promise in the treatment of patients with recurrent high-grade …